Investigational Drug Information for AZD7594
✉ Email this page to a colleague
What is the development status for investigational drug AZD7594?
AZD7594 is an investigational drug.
There have been 10 clinical trials for AZD7594.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 2nd 2019.
The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are AstraZeneca, Parexel, and Quotient Sciences.
There are ten US patents protecting this investigational drug and one hundred and eighty-one international patents.
Summary for AZD7594
| US Patents | 10 |
| International Patents | 181 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-01-02) |
| Vendors | 26 |
Recent Clinical Trials for AZD7594
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects. | Parexel | Phase 1 |
| A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects. | AstraZeneca | Phase 1 |
| A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma | Parexel | Phase 1 |
Clinical Trial Summary for AZD7594
Top disease conditions for AZD7594
Top clinical trial sponsors for AZD7594
US Patents for AZD7594
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD7594 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| AZD7594 | ⤷ Try a Trial | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| AZD7594 | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| AZD7594 | ⤷ Try a Trial | Phenyl and benzodioxinyl substituted indazoles derivatives | AstraZeneca AB (Sodertalje, SE) Bayer Schering Pharma AG (Berlin, DE) | ⤷ Try a Trial |
| AZD7594 | ⤷ Try a Trial | Phenyl and benzodioxinyl substituted indazoles derivatives | Astrazeneca AB (Sodertalje, SE) Bayer Pharma Aktiengesellschaft (Berlin, DE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD7594
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD7594 | Argentina | AR099177 | 2034-01-24 | ⤷ Try a Trial |
| AZD7594 | Australia | AU2015208932 | 2034-01-24 | ⤷ Try a Trial |
| AZD7594 | Australia | AU2017200338 | 2034-01-24 | ⤷ Try a Trial |
| AZD7594 | Australia | AU2018202956 | 2034-01-24 | ⤷ Try a Trial |
| AZD7594 | Australia | AU2019202675 | 2034-01-24 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
